tirzepatide still available is compound Tirzepatide — Compounded dual GIP/GLP-1 medication Tirzepatide for Weight Loss -

Retatrutide is an investigational medication that hasnt been approved by the MHRA

Researchers concluded this could be because females have a lower average body weight compared to males, which allowed for more exposure to the drug

Stopping treatment suddenly can lead to weight regain GLP-1 medicines help manage appetite, so stopping them quickly can bring back old eating patterns

In further support of this ex vivo finding, the GIPR monoagonist LY3537021 reduced body weight by ~4.1% over 8 weeks in patients with T2D (n = 18) (57)

Prepaying a longer subscription term can lower the per-month rate in exchange for a larger up-front commitment